Background: Due to the high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson disease (PD), routine cognitive screening is important for the optimal management of patients with PD. The Montreal Cognitive Assessment (MoCA) is more sensitive than the commonly used Mini-Mental State Examination (MMSE) in detecting MCI and dementia in patients without PD, but its validity in PD has not been established.
The long-term, cumulative prevalence of dementia in Parkinson disease (PDD) is as high as 80%, 1 and impairment not meeting criteria for dementia (i.e., mild cognitive impairment [MCI]) has been reported to occur in 20%-30% of patients with PD, 2-4 even among those patients newly diagnosed, 2, 5 and appears to be twice as common in PD patients without dementia as in healthy elders. 6 Cognitive impairment in PD patients without dementia has been found to predict future cognitive decline, including development of PDD. 3, 4, 7 Additionally, the presence of cognitive impairment in PD patients without dementia is associated with worse health-related quality of life (QOL) 8 and functional impairment. 9 For these reasons and to assist with clinical management, recognition of cognitive disorders in PD is important. However, few screening instruments for global cognition are brief, appro-priate for use in routine clinical care, and validated in PD. The Mini-Mental State Examination (MMSE) is the most commonly used instrument in PD, despite its lack of validation in this population. Previous research has called into question its accuracy and sensitivity in PD, [10] [11] [12] [13] [14] [15] yet it is still recommended and used as the primary screening instrument for dementia in PD. 16 The Montreal Cognitive Assessment (MoCA) 17 was developed as a brief screening instrument for MCI and mild Alzheimer disease (AD) to address limitations of the MMSE. The MoCA is divided into 7 subscores: visuospatial/executive (5 points); naming (3 points); memory (5 points for delayed recall); attention (6 points); language (3 points); abstraction (2 points); and orientation (6 points). One point is added if the subject has Յ12 years of education.
The MoCA has been shown to be more sensitive than the MMSE for the detection of MCI and mild AD in the general population, and a score Յ25 was found to be the optimal cutoff point for a diagnosis of cognitive impairment. 17 A study of MoCA performance in patients with PD with normal MMSE scores found 52% of subjects had cognitive impairment using this cutoff point. 13 One study that compared MoCA and MMSE performance in PD found the MoCA to be more sensitive than the MMSE in detecting cognitive impairment, but a MMSE score Ͻ26 was used to classify patients as having cognitive impairment, and this MMSE cutoff point has not been validated in PD. 12 Finally, another study found that the MoCA has good test-retest reliability, interrater reliability, and convergent validity with a neuropsychological battery in a small sample of patients with PD. 18 Given the promising preliminary results on the utility of the MoCA in PD as a screening instrument for cognitive impairment compared with the MMSE, the aim of this study was to assess the discriminant validity of both the MoCA and the MMSE to detect MCI and dementia in PD using established diagnostic criteria as well as operationalized criteria for defining cognitive deficits on the basis of a neuropsychological test battery.
METHODS Subjects. A convenience sample of 132 patients (no cognitive disorder ϭ 92; MCI ϭ 23; PDD ϭ 17) with idiopathic PD at 2 movement disorders clinics was assessed between August 2006 and April 2009. The diagnosis of possible or probable PD was confirmed by the patient's movement disorder neurologist according to established criteria. 19 Patients who had undergone deep brain stimulation (DBS) within the previous 6 months were excluded from the study.
Standard protocol approval and patient consents. The
Institutional Review Board at each participating institution approved the study, and written informed consent was obtained from subjects prior to study participation. 22 and Semantic Verbal Fluency 23 ), attention (Backward Digit Span), and visuospatial (Cube Copying, which was extracted from the MoCA and rescored for this purpose using a more detailed methodology outlined below). When standardized scores were available, a score Ն1.5 SD below the published normative data mean was considered to represent a "deficit," which is consistent with previous PD research. 3, 6 Memory deficit was defined as Ն1.5 SD below the published normative data mean on at least 1 of 2 HVLT measures (immediate free recall or recognition discrimination). Executive deficit was Ն1.5 SD below the normative data mean on 1 of 2 TOL DX measures (total moves or total correct scores), the Stroop Color-Word mismatch, or Verbal Fluency. Attention deficit was a score Յ4 on the Backward Digit Span, as recommended for the elderly. 24 Finally, visuospatial deficit was a score of 0 -2 on a 5-point scale scoring method for Cube Copying. 25 Due to impaired color discrimination, approximately 10% of subjects were unable to perform the Stroop. MoCA and MMSE questionnaires with incomplete questions that constituted Յ3 points (10% of total points) were included with a prorated score.
Procedures
The median time interval between administration of the MoCA or MMSE and the neuropsychological battery was 5 weeks. Subjects who completed the battery over 6 months after the index tests were excluded from analysis.
Diagnostic criteria for MCI and dementia. A Movement
Disorder Society task force recommended diagnostic criteria for probable PDD 16, 26 that included cognitive deficits in at least 2 of the 4 core cognitive domains (attention, executive functions, visuospatial, and memory), as well as cognitive deficiency severe enough to impair daily life (e.g., inability to manage finances and cope in social situations). Therefore, our dementia criteria were 1) Ն1.5 SD below the normative data mean on tests in at least 2 cognitive domains, 2) self-report of cognitive decline, and 3) impairment of instrumental activities of daily living (IADLs).
A modification of the Peterson criteria 27 that allows for impairments in a range of cognitive domains, called the Winblad criteria, 28 was used to diagnose MCI. Our MCI criteria were 1) Ն1.5 SD below the normative data mean on tests in at least 1 cognitive domain, 2) self-report of cognitive decline, and 3) preserved IADLs. Subjective reports of cognitive decline and impairment in IADLs were obtained from subjects by the study PI (D.W.) during an unstructured interview (in person or by telephone, asking participants if they had noted any meaningful change over the course of PD in their ability to plan, remember, pay attention, or complete tasks), and when available the input of informed others was solicited. Formal diagnostic criteria for MCI and PDD were applied by the study PI, who was blinded to MoCA and MMSE scores.
Five subjects failed to fit into 1 of the 3 diagnostic categories (PDD, MCI, or normal), as they had deficits in only 1 cognitive domain but reported functional impairment. These 5 subjects were excluded from the validation process.
Other clinical measures. The 15-item Geriatric Depression
Scale (GDS-15) was administered to measure severity of depression symptomatology (scores ranging from 0 to 15, higher scores indicating greater depression severity). 29 The Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and disease severity as measured by Hoehn & Yahr stage (scores ranging from 1 to 5, higher scores indicating greater disease severity) 30 were obtained from the subjects or by chart review. Patients were encouraged to take their regularly scheduled PD medications during the study visit so that they would be evaluated in their "on" state.
Analyses. Between-group comparisons of demographic and clinical characteristics, including MoCA and MMSE scores, between cognitively impaired (i.e., those meeting criteria for either MCI or PDD) and unimpaired samples were performed using either an independent-sample t test with Levene's test for equality of variances or a Pearson 2 test for dichotomous variables.
A receiver operating characteristic (ROC) with area under the curve (AUC) (95% CI) was plotted for each of the instruments' discriminant validity for detecting any cognitive disorder (MCI or PDD) vs absence of a cognitive disorder, as this is often the primary comparison when assessing the validity of cognitive screening instruments. 31 Secondary analyses included examining each questionnaire's discriminant validity for detecting MCI alone (vs no cognitive disorder), PDD alone (vs no cognitive disorder), and deficits on neuropsychological testing (Ն2 domains, without the requirement of self-report of cognitive decline) vs no neuropsychological deficits. The AUC, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and percent correctly diagnosed were calculated for each questionnaire. The optimal screening cutoff point was defined as the lowest value that achieved Ͼ80% sensitivity and NPV; the optimal diagnostic cutoff point was defined as the highest value that achieved Ͼ80% specificity and PPV.
All statistical procedures were performed with SPSS 15.0 for Windows. 32 RESULTS Subject characteristics. The figure is a flow diagram of study participants, 33 MoCA and MMSE performance for the subjects who had cognitive deficits on neuropsychological testing (Ն1 domain) but did not report cognitive decline (n ϭ 39) was compared with the MCI group (n ϭ 23), who also had to report cognitive decline in order to meet MCI diagnostic criteria. Controlling for age, sex, and educational level, there were no sig- are to be used as diagnostic instruments instead of screening instruments. The MMSE has been recommended as a useful tool to identify cognitively impaired patients with PD, 16 but our results suggest several factors that recommend the MoCA for use over the MMSE as a screening instrument. The optimal screening cutoff point for detection of any cognitive disorder for the MoCA had greater specificity (0.53), PPV (0.46), and percent correctly diagnosed (64%) than the optimal MMSE screening cutoff point (specificity ϭ 0.38; PPV ϭ 0.39; percent correctly diagnosed ϭ 54%). In addition, the MoCA produced a larger range of scores (12-30; range ϭ 19 points) compared to the MMSE (22-30; range ϭ 9 points). Finally, the optimal MMSE screening cutoff point of 29/30 means that only patients scoring a perfect 30 are considered to have a negative screen for the detection of a cognitive disorder.
Given that cognitive impairment 1) is common throughout the course of PD; 2) typically progresses to PDD long-term; 3) adversely impacts function, QOL, and caregiver burden; and 4) should inform clinical decision-making, including use of cognitive enhancing agents, it is important that patients with PD at all stages of the disease undergo routine screening of global cognitive abilities in the context of clinical care. Our research is consistent with most research to date that the MMSE does not perform well as a screening instrument for MCI and PDD, 34 18  18  20  28  35  45  48  70  80  90  93  100  100   Specificity  99  98  96  94  91  90  85  75  64  53  39  22  10   PPV  88  78  67  65  64  78  58  55  49  46  40  36  32   NPV  73  73  73  75  76  79  79  85  88  92  92  100 part to lack of sensitivity to milder cognitive deficits (i.e., instrument ceiling effect, 35 with 29.5% of patients achieving a perfect score on the MMSE, compared with 6.8% on the MoCA). Both the Mattis Dementia Rating Scale 36 and the Cambridge Cognitive Assessment have been validated against a DSM-IV 37 diagnosis of dementia, 38 but their completion times are too long to be appropriate for use in routine clinical care (approximately 20 -45 minutes for these instruments compared with less than 10 minutes for the MoCA). Other global cognitive instruments recently developed for use in PD with preliminary evidence to support their validity include the Parkinson Neuropsychometric Dementia Assessment 11 and the PD-Cognitive Rating Scale, 39 but neither validation study operationalized the definition of impairment on neuropsychological testing to support a cognitive disorder diagnosis, and the latter instrument takes 17-26 minutes to complete. An interesting finding of our study regards apparent limitations in the value of self-report of cognitive decline and functional impairment in the context of a clinical research interview. Sixty-two of the 115 subjects without dementia (53.9%) had impaired cognitive testing in Ն1 domain, and 39 of the 62 (62.9%) did not self-report cognitive decline that would have led to a diagnosis of MCI. Similarly, of the 30 patients who had impairments in Ն2 cognitive domains and were eligible for a diagnosis of dementia, 13 of the 30 (43.3%) denied any functional impairment that would have led to a diagnosis of PDD. However, there were no significant betweengroup differences in MoCA or MMSE scores for patient groups distinguished by these self-reports. Additional study is needed to determine if self-report of cognitive decline or functional impairment is of clinical or prognostic significance in this population.
due in
Regarding study limitations, our results may not be generalizable, as the majority of our patients were male, white, and highly educated, and all were recruited from specialty care centers. Second, while the MoCA includes a minor correction for lower educational levels, the MMSE does not, which affects the diagnostic accuracy of the latter in highly educated individuals. 40 Third, the majority of patients had mild to moderate PD (i.e., Hoehn & Yahr stages 1-3). Fourth, we did not have a matched non-PD control group, although the goal of the study was not to compare cognitive functioning in patients with PD and non-PD patients. Furthermore, our neuropsychological battery had more detailed testing of memory and executive functioning compared with attention and visuospatial functioning, and there was no assessment of language abilities. Although there is no consensus regarding the ideal neuropsychological battery to detect cognitive deficits in PD, our battery may have led to an underestimation of PDD and MCI frequencies in our study population. Finally, the number of MCI and PDD cases relative to unimpaired patients was relatively low, and including 29  29  35  41  53  65  65  82  82  100  100  100  100   Specificity  99  98  96  94  91  90  85  75  64  53  39  22  10   PPV  83  71  60  54  53  55  44  38  30  28  23  19 more patients with a cognitive disorder would lend more certainty to our findings and improve the PPV of both instruments. However, our study sample seemed to be representative of the overall population at these 2 movement disorders centers. While the reported point prevalence of PDD and MCI is typically higher than in our study population, this would not affect our findings regarding the sensitivities and specificities of the 2 screening instruments. Due to the sample size limitations, we were not able to validate the optimal cutoff points in a separate sample, so additional studies of the MoCA and MMSE in PD are needed. Given the high prevalence of dementia in PD and the high conversion rate of MCI to PDD, early and routine screening for cognitive impairment with a brief, sensitive instrument is warranted. Our study recommends the MoCA over the widely used MMSE and suggests the need for further validation of the MoCA and MMSE in a larger sample of patients with PD, against other screening instruments, and using a more detailed neuropsychological battery.
